Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 17/20 | 0.55 |
| ▸ | DRD2 | P14416 | 4/20 | 0.55 |
| ▸ | HTR2A | P28223 | 4/20 | 0.55 |
| ▸ | HTR7 | P34969 | 4/20 | 0.55 |
| ▸ | HTR1A | P08908 | 1/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | CA12 | O43570 | 1/20 | 0.48 |
| ▸ | CA1 | P00915 | 1/20 | 0.48 |
| ▸ | CA2 | P00918 | 1/20 | 0.48 |
| ▸ | CA9 | Q16790 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29429815 | 0.88 | HTR6 (0.56) | HTR6DRD2HTR2AHTR7HTR1A | |
| SCHEMBL6039811 | 0.88 | HTR6 (0.56) | HTR6DRD2HTR2AHTR7HTR1A | |
| SCHEMBL21549443 | 0.86 | HTR6 (0.61) | HTR6DRD2HTR2AHTR7HTR1A | |
| SCHEMBL20190392 | 0.86 | HTR6 (0.54) | HTR6DRD2HTR2AHTR7HTR1A | |
| SCHEMBL6039554 | 0.86 | HTR6 (0.58) | HTR6DRD2HTR2AHTR7HTR1A | |
| SCHEMBL28313363 | 0.84 | HTR6 (0.53) | HTR6DRD2HTR2AHTR7HTR1A | |
| SCHEMBL28312482 | 0.83 | HTR6 (0.48) | HTR6DRD2HTR2AHTR7HTR1A | |
| SCHEMBL25219570 | 0.82 | HTR6 (0.50) | HTR6DRD2HTR2AHTR7HTR1A | |
| SCHEMBL29993908 | 0.81 | HTR6 (0.46) | HTR6DRD2HTR2AHTR7HTR1A | |
| SCHEMBL28862184 | 0.81 | HTR6 (0.46) | HTR6DRD2HTR2AHTR7HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3057956-B1 | POLYCYCLIC INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | DANA FARBER CANCER INST INC (US) | 2021-05-05 | — | — | EP | disclosed |
| US-20210061803-A1 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | SYROS PHARMACEUTICALS INC (US) | 2021-03-04 | — | — | US | disclosed |
| US-20210061803-A1 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | SYROS PHARMACEUTICALS INC (US) | 2021-03-04 | — | — | US | disclosed |
| US-10906889-B2 | Polycyclic inhibitors of cyclin-dependent kinase 7 (CDK7) | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2021-02-02 | — | — | US | disclosed |
| US-10906889-B2 | Polycyclic inhibitors of cyclin-dependent kinase 7 (CDK7) | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2021-02-02 | — | — | US | disclosed |
| US-10865206-B2 | Inhibitors of cyclin-dependent kinase 7 (CDK7) | SYROS PHARMACEUTICALS, INC. (US) | 2020-12-15 | — | — | US | disclosed |
| US-10865206-B2 | Inhibitors of cyclin-dependent kinase 7 (CDK7) | SYROS PHARMACEUTICALS, INC. (US) | 2020-12-15 | — | — | US | disclosed |
| CN-105849099-B | Polycyclic inhibitors of cyclin dependent kinase 7(CDK7) | 达纳-法伯癌症研究所股份有限公司 | 2020-01-17 | — | — | CN | disclosed |
| US-20190337940-A1 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2019-11-07 | — | — | US | disclosed |
| US-20190337940-A1 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2019-11-07 | — | — | US | disclosed |
| US-10308648-B2 | Inhibitors of cyclin-dependent kinase 7 (CDK7) | SYROS PHARMACEUTICALS, INC. (US) | 2019-06-04 | — | — | US | disclosed |
| US-20190031642-A1 | POLYCYCLIC INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | PARAZA PHARMA, INC. (CA) | 2019-01-31 | — | — | US | disclosed |
| US-20170327496-A1 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2017-11-16 | — | — | US | disclosed |
| US-20160264554-A1 | POLYCYCLIC INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | DANA-FARBER CANCER INSTITUTE, INC. | 2016-09-15 | — | — | US | disclosed |
| EP-3057956-A1 | POLYCYCLIC INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | Dana-Farber Cancer Institute, Inc. (US) | 2016-08-24 | — | — | EP | disclosed |
| WO-2015058140-A1 | POLYCYCLIC INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2015-04-23 | — | — | WO | disclosed |
| WO-2014155300-A2 | SUBSTITUED PYRIMIDINE AMINE DERIVATIVES AS TAK-1 INHIBITORS | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2014-10-02 | — | — | WO | disclosed |
| WO-2006038001-A1 | AMINOPYRIMIDINE DERIVATIVES AS JNK INHIBITORS | CELLTECH R & D LIMITED (GB) | 2006-04-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10906889-B2 | Polycyclic inhibitors of cyclin-dependent kinase 7 (CDK7) | CDK13, CDK3, CDK12 | HTR6 3698/4885DRD2 4674/4885HTR2A 4265/4885 |
| US-20190337940-A1 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | CDK7, CDK3, CDK9 | HTR6 3520/4885DRD2 4755/4885HTR2A 4656/4885 |
| US-20190031642-A1 | POLYCYCLIC INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | CDK13, CDK3, CDK12 | HTR6 3698/4885DRD2 4674/4885HTR2A 4265/4885 |
| US-10308648-B2 | Inhibitors of cyclin-dependent kinase 7 (CDK7) | CDK7, CDK3, CDK9 | HTR6 3520/4885DRD2 4755/4885HTR2A 4656/4885 |
| US-20160264554-A1 | POLYCYCLIC INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | CDK13, CDK3, CDK12 | HTR6 3698/4885DRD2 4674/4885HTR2A 4265/4885 |
| US-20170327496-A1 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | CDK7, CDK3, CDK9 | HTR6 3520/4885DRD2 4755/4885HTR2A 4656/4885 |
| US-20210061803-A1 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | CDK7, CDK3, CDK9 | HTR6 3520/4885DRD2 4755/4885HTR2A 4656/4885 |
| US-10865206-B2 | Inhibitors of cyclin-dependent kinase 7 (CDK7) | CDK7, CDK3, CDK9 | HTR6 3520/4885DRD2 4755/4885HTR2A 4656/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.